Cantor Fitzgerald Issues Positive Forecast for CRSP Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Analysts at Cantor Fitzgerald increased their FY2025 earnings estimates for CRISPR Therapeutics in a research note issued on Wednesday, May 7th. Cantor Fitzgerald analyst E. Schmidt now anticipates that the company will post earnings per share of ($6.71) for the year, up from their prior forecast of ($6.91). Cantor Fitzgerald has a “Neutral” rating on the stock. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.16) per share.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. The firm’s revenue for the quarter was up 71.6% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.43) EPS.

Several other brokerages have also weighed in on CRSP. Barclays dropped their price objective on shares of CRISPR Therapeutics from $56.00 to $42.00 and set an “equal weight” rating on the stock in a research report on Friday. Royal Bank of Canada dropped their price objective on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating for the company in a research note on Wednesday, February 12th. Morgan Stanley upped their target price on CRISPR Therapeutics from $30.00 to $32.00 and gave the company an “underweight” rating in a research report on Friday, February 14th. Truist Financial raised their price target on CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a “buy” rating in a research report on Wednesday, February 12th. Finally, StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a research note on Friday, March 21st. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $73.12.

CRISPR Therapeutics Trading Down 1.4 %

CRSP stock opened at $35.62 on Friday. CRISPR Therapeutics has a 1-year low of $30.04 and a 1-year high of $67.88. The business’s 50 day simple moving average is $38.15 and its 200 day simple moving average is $42.77. The firm has a market capitalization of $3.08 billion, a PE ratio of -8.15 and a beta of 1.88.

Hedge Funds Weigh In On CRISPR Therapeutics

A number of hedge funds have recently bought and sold shares of CRSP. Intellectus Partners LLC increased its position in shares of CRISPR Therapeutics by 3.6% during the 4th quarter. Intellectus Partners LLC now owns 7,131 shares of the company’s stock valued at $281,000 after purchasing an additional 250 shares during the last quarter. Farrow Financial Inc. increased its holdings in CRISPR Therapeutics by 1.4% during the fourth quarter. Farrow Financial Inc. now owns 20,097 shares of the company’s stock worth $777,000 after buying an additional 270 shares during the last quarter. Kestra Private Wealth Services LLC boosted its stake in CRISPR Therapeutics by 1.5% in the fourth quarter. Kestra Private Wealth Services LLC now owns 20,636 shares of the company’s stock valued at $812,000 after acquiring an additional 310 shares during the last quarter. SFE Investment Counsel grew its position in shares of CRISPR Therapeutics by 5.8% during the 1st quarter. SFE Investment Counsel now owns 6,507 shares of the company’s stock valued at $221,000 after acquiring an additional 355 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of CRISPR Therapeutics by 7.6% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 5,252 shares of the company’s stock worth $215,000 after purchasing an additional 372 shares during the last quarter. Institutional investors own 69.20% of the company’s stock.

Insider Transactions at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 18,360 shares of the company’s stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total value of $1,013,472.00. Following the sale, the chief executive officer now owns 171,613 shares in the company, valued at approximately $9,473,037.60. The trade was a 9.66 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Julianne Bruno sold 1,198 shares of the firm’s stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total value of $50,819.16. Following the transaction, the chief operating officer now owns 8,263 shares of the company’s stock, valued at $350,516.46. This trade represents a 12.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 32,381 shares of company stock worth $1,608,243. Company insiders own 4.30% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.